FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048949051> ?p ?o ?g. }

• W2048949051 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground:Regorafenib (BAY 73-4506) is the first small molecule tyrosine kinase inhibitor that has been approved for treatment of advanced CRC. In the Correct trial*, 1% of the participants showed a partial response and 42.8 % had stable disease. KRAS wild type and mutants showed equal response rates.Regorafenib is a multityrosine kinase inhibitor with nM IC50's against CRAF, VEGFR2, KIT and RET and is about tenfold less potent for BRAF, BRAFV600E, PDGFRβ and VEGFR1 and 3. We tested the effect of regorafenib and other angiogenic inhibitors on patient-derived kinases in treatment naive primary colon tumor samples for potency and selectivity of inhibition.Method:Colon tumor tissue from patients who had given informed consent was fresh frozen after surgical resection. All tumor specimens were analysed for BRAF and KRAS mutation status. Tissue cryosections were lysed in buffer with phosphatase and protease inhibitors. Phosphotyrosine kinase (PTK) and serine/threonine kinase (STK) activity profiles of tumour tissue were generated on PamChip® peptide microarrays comprising hundreds of peptide sequences derived from known human phosphorylation sites. The ex vivo effect of kinase inhibitors on these kinase activity profiles was determined. Peptide phosphorylation was monitored using fluorescently labelled antibodies. Data were analysed with Bionavigator software.Result:Kinase activity profiles were obtained from 16 CRC patient tumors for both tyrosine as well as serine/threonine specific peptide phosphorylations. Direct enzymatic inhibition of tumor-derived PTK activity was observed in all 16 samples at low micromolar concentrations (3 µM) of spiked-in regorafenib. For the serine/threonine kinase activity, spiking in of a high concentration of regorafenib (50 µM) resulted in only low levels of inhibition of phosphorylations on a subset of peptides, including BRAF substrate peptides. No difference in inhibition was observed between KRAS and BRAF mutants and wild type tumors. Furthermore the non-inhibited kinase activity profiles did not correlate to mutation status either.Conclusion:For the first time the direct biochemical effect of regorafenib has been tested on primary tumor tissue from CRC patients. These data support previous findings suggesting that regorafenib, besides its angiogenic activity on vasothelial cells, can inhibit oncogenic tyrosine kinases in the tumor. These results will be a basis for biomarker analysis by correlating on-chip drug effects to clinical responses.*Grothey et al, Lancet 2013 381(9863):303-312Citation Format: Maria H. Hilhorst, Rosanne van den Oord, Hans Pruijt, Adriaan van den Brule, Peet Nooijen, Rik de Wijn, Liesbeth Houkes. Direct effect of regorafenib on tyrosine kinase activities in treatment naive colorectal cancer (CRC) primary tumor tissue. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5511. doi:10.1158/1538-7445.AM2014-5511" @default.
• W2048949051 created "2016-06-24" @default.
• W2048949051 creator A5014789788 @default.
• W2048949051 creator A5036303401 @default.
• W2048949051 creator A5038901928 @default.
• W2048949051 creator A5052145510 @default.
• W2048949051 creator A5061566596 @default.
• W2048949051 creator A5065342954 @default.
• W2048949051 creator A5089466522 @default.
• W2048949051 date "2014-09-30" @default.
• W2048949051 modified "2023-09-27" @default.
• W2048949051 title "Abstract 5511: Direct effect of regorafenib on tyrosine kinase activities in treatment naive colorectal cancer (CRC) primary tumor tissue" @default.
• W2048949051 doi "https://doi.org/10.1158/1538-7445.am2014-5511" @default.
• W2048949051 hasPublicationYear "2014" @default.
• W2048949051 type Work @default.
• W2048949051 sameAs 2048949051 @default.
• W2048949051 citedByCount "0" @default.
• W2048949051 crossrefType "proceedings-article" @default.
• W2048949051 hasAuthorship W2048949051A5014789788 @default.
• W2048949051 hasAuthorship W2048949051A5036303401 @default.
• W2048949051 hasAuthorship W2048949051A5038901928 @default.
• W2048949051 hasAuthorship W2048949051A5052145510 @default.
• W2048949051 hasAuthorship W2048949051A5061566596 @default.
• W2048949051 hasAuthorship W2048949051A5065342954 @default.
• W2048949051 hasAuthorship W2048949051A5089466522 @default.
• W2048949051 hasConcept C11960822 @default.
• W2048949051 hasConcept C121608353 @default.
• W2048949051 hasConcept C126322002 @default.
• W2048949051 hasConcept C153911025 @default.
• W2048949051 hasConcept C184235292 @default.
• W2048949051 hasConcept C185592680 @default.
• W2048949051 hasConcept C2776248978 @default.
• W2048949051 hasConcept C2781187634 @default.
• W2048949051 hasConcept C42362537 @default.
• W2048949051 hasConcept C502942594 @default.
• W2048949051 hasConcept C526805850 @default.
• W2048949051 hasConcept C55493867 @default.
• W2048949051 hasConcept C62478195 @default.
• W2048949051 hasConcept C71924100 @default.
• W2048949051 hasConcept C86803240 @default.
• W2048949051 hasConceptScore W2048949051C11960822 @default.
• W2048949051 hasConceptScore W2048949051C121608353 @default.
• W2048949051 hasConceptScore W2048949051C126322002 @default.
• W2048949051 hasConceptScore W2048949051C153911025 @default.
• W2048949051 hasConceptScore W2048949051C184235292 @default.
• W2048949051 hasConceptScore W2048949051C185592680 @default.
• W2048949051 hasConceptScore W2048949051C2776248978 @default.
• W2048949051 hasConceptScore W2048949051C2781187634 @default.
• W2048949051 hasConceptScore W2048949051C42362537 @default.
• W2048949051 hasConceptScore W2048949051C502942594 @default.
• W2048949051 hasConceptScore W2048949051C526805850 @default.
• W2048949051 hasConceptScore W2048949051C55493867 @default.
• W2048949051 hasConceptScore W2048949051C62478195 @default.
• W2048949051 hasConceptScore W2048949051C71924100 @default.
• W2048949051 hasConceptScore W2048949051C86803240 @default.
• W2048949051 hasLocation W20489490511 @default.
• W2048949051 hasOpenAccess W2048949051 @default.
• W2048949051 hasPrimaryLocation W20489490511 @default.
• W2048949051 hasRelatedWork W1522122448 @default.
• W2048949051 hasRelatedWork W1963905418 @default.
• W2048949051 hasRelatedWork W1965188536 @default.
• W2048949051 hasRelatedWork W1970495216 @default.
• W2048949051 hasRelatedWork W1971519331 @default.
• W2048949051 hasRelatedWork W2029536410 @default.
• W2048949051 hasRelatedWork W2054177711 @default.
• W2048949051 hasRelatedWork W2096218887 @default.
• W2048949051 hasRelatedWork W2100270799 @default.
• W2048949051 hasRelatedWork W2124797061 @default.
• W2048949051 hasRelatedWork W2125569903 @default.
• W2048949051 hasRelatedWork W2171406886 @default.
• W2048949051 hasRelatedWork W2330501746 @default.
• W2048949051 hasRelatedWork W2487905146 @default.
• W2048949051 hasRelatedWork W2802637662 @default.
• W2048949051 hasRelatedWork W2885843977 @default.
• W2048949051 hasRelatedWork W2954826200 @default.
• W2048949051 hasRelatedWork W2955118479 @default.
• W2048949051 hasRelatedWork W2967096478 @default.
• W2048949051 hasRelatedWork W3082445649 @default.
• W2048949051 isParatext "false" @default.
• W2048949051 isRetracted "false" @default.
• W2048949051 magId "2048949051" @default.
• W2048949051 workType "article" @default.